Response commentary: exosomes vs microvesicles in hematological malignancies.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Extra-nuclear histones: origin, significance and perspectives.Molecular and cellular biochemistry · 2022
   Review
2. MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease.Cancers · 2021
   Review
3. MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance.International journal of molecular sciences · 2020
   Review
4. Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment.Seminars in immunology · 2018
   Review

Corrections and comments

• Comment on
  Do we need to distinguish exosomes from microvesicles in hematological malignancies?2017

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as